{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:04:59Z","timestamp":1747181099654,"version":"3.40.5"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,4]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Eosinophilic granulomatosis with polyangiitis (EGPA) is belongs to the antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) subgroups. EGPA, unlike other subgroups of AAV, including microscopic polyangiitis (MPA) and granulomatosis with polyangiitis, has the unique feature that both ANCA and eosinophilic inflammation are involved in its pathogenesis. Although AAV often relapses, there are currently no reports of EGPA developing during other subgroups of AAV. Herein, we document a case of EGPA that developed during the clinical course of MPA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 61-year-old Japanese woman was diagnosed with MPA based on interstitial lung disease and myeloperoxidase-ANCA positivity. After starting immunosuppression therapy, including prednisolone and tacrolimus, she was expected to achieve clinical remission. Nonetheless, she occasionally experienced MPA relapse, which required an increased prednisolone dose, rituximab, intravenous cyclophosphamide, and plasma exchange. Three years after MPA onset, she developed renal amyloidosis; thus, subcutaneous tocilizumab was added to her regimen. Following clinical remission, the administration interval of her subcutaneous tocilizumab therapy was extended and immunosuppressants were discontinued. She then developed bronchial asthma and mild eosinophilia (eosinophilic count: ~1000\/\u03bcL). Further, a year later, she underwent total hip replacement using a titanium implant. Subsequently, she developed abnormal sensation in both hands, numbness, and muscle weakness, as well as palpable purpura and massive eosinophilia (eosinophilic count: ~8500\/\u03bcL).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>We diagnosed the patient with EGPA based on 5 items (asthma, multiple mononeuropathies, sinus abnormality, and extravascular eosinophils) of the 1990 American College of Rheumatology classification criteria.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>We administered 400\u2009mg\/kg intravenous immunoglobulin for 5 consecutive days, 300\u2009mg mepolizumab subcutaneously every 4 weeks, and 40\u2009mg\/day prednisolone following pulsed methylprednisolone therapy (1000\u2009mg\/day for 3 consecutive days).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After these treatments, the patient\u2019s symptoms improved, and eosinophilic count and inflammatory markers declined.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>The present case suggests that EGPA can be induced by the development of eosinophilic inflammation in other subgroups of AAV.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000031401","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T19:15:22Z","timestamp":1667848522000},"page":"e31401","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Development of eosinophilic granulomatosis with polyangiitis during the clinical course of microscopic polyangiitis: A case report"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5120-4976","authenticated-orcid":false,"given":"Hiroyuki","family":"Ide","sequence":"first","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0036-2039","authenticated-orcid":false,"given":"Toshimasa","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"},{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Koike","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniko","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Pathology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Shigematsu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Nishihata","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Ichinose","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international chapel hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0140-6736(06)69114-9","article-title":"Antineutrophil cytoplasmic antibodies","volume":"368","author":"Bosch","year":"2006","journal-title":"Lancet"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41584-018-0145-y","article-title":"Pathogenesis and therapeutic interventions for ANCA-associated vasculitis","volume":"15","author":"Nakazawa","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nrrheum.2014.98","article-title":"Eosinophils in vasculitis: characteristics and roles in pathogenesis","volume":"10","author":"Khoury","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.alit.2019.06.004","article-title":"Update on eosinophilic granulomatosis with polyangiitis","volume":"68","author":"Furuta","year":"2019","journal-title":"Allergol Int"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/art.1780330806","article-title":"The American college of rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)","volume":"33","author":"Masi","year":"1990","journal-title":"Arthritis Rheum"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/cea.13209","article-title":"Innate immune response reflects disease activity in eosinophilic granulomatosis with polyangiitis","volume":"48","author":"Tsurikisawa","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/nature08900","article-title":"Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity","volume":"464","author":"Neill","year":"2010","journal-title":"Nature"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nri3349","article-title":"Innate lymphoid cells\u2014how did we miss them?","volume":"13","author":"Walker","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/annrheumdis-2021-221796","article-title":"2022 American college of rheumatology\/European alliance of associations for rheumatology classification criteria for microscopic polyangiitis","volume":"81","author":"Suppiah","year":"2022","journal-title":"Ann Rheum Dis Am College Rheumatol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American college of rheumatology\/European alliance of associations for rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/hmg\/ddx053","article-title":"Neutrophil-mediated IL-6 receptor trans-signaling and the risk of chronic obstructive pulmonary disease and asthma","volume":"26","author":"Farahi","year":"2017","journal-title":"Hum Mol Genet"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0161-5890(02)00210-9","article-title":"The two faces of IL-6 on Th1\/Th2 differentiation","volume":"39","author":"Diehl","year":"2002","journal-title":"Mol Immunol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/mrcr\/rxab010","article-title":"A case of eosinophilic granulomatosis with polyangiitis after prolonged intervals of an anti-interleukin-6 receptor antibody for rheumatoid arthritis","volume":"6","author":"Imai","year":"2022","journal-title":"Mod Rheumatol Case Rep"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/jbm.a.32390","article-title":"Titanium induced production of chemokines CCL17\/TARC and CCL22\/MDC in human osteoclasts and osteoblasts","volume":"92","author":"Cadosch","year":"2010","journal-title":"J Biomed Mater Res A"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11926-020-0881-2","article-title":"Eosinophilic vasculitis","volume":"22","author":"Vega Villanueva","year":"2020","journal-title":"Curr Rheumatol Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:20:07Z","timestamp":1746328807000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":16,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000031401","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,11,4]]}}}